What is EnsoData?
Headquartered in Madison, Wisconsin, EnsoData specializes in the development of sophisticated software solutions designed to track and analyze vital health metrics, including heart rhythm and glycemic indices. By integrating machine learning with clinical workflows, the company provides healthcare providers with actionable insights that improve patient outcomes and operational efficiency. EnsoData operates at the intersection of artificial intelligence and medical diagnostics, positioning itself as a vital partner for health systems seeking to modernize their data analysis capabilities. The firm's technology is increasingly recognized for its ability to automate complex diagnostic processes, thereby reducing the burden on clinical staff while enhancing the precision of patient care.
How much funding has EnsoData raised?
EnsoData has raised a total of $50.7M across 5 funding rounds:
Angel/Seed
$550K
Private Equity
$987K
Debt
$150K
Series A
$29M
Series B
$20M
Angel/Seed (2016): $550K with participation from HealthX Ventures
Private Equity (2017): $987K, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Series A (2022): $29M featuring Inspire Medical Systems, Venture Investors, and Zetta Venture Partners
Series B (2025): $20M backed by Zetta Venture Partners, Questa Capital, Supermoon Capital, and Inspire Medical Systems
Key Investors in EnsoData
Zetta Venture Partners
A venture capital firm specializing in early-stage AI-native startups, providing hands-on support to founders building critical infrastructure and developer tools.
Questa Capital
A growth-oriented investment firm focused on innovative healthcare companies that aim to enhance patient experiences, reduce costs, and improve population health outcomes.
Supermoon Capital
A specialized venture capital platform dedicated to supporting visionary founders who are innovating in the field of sleep health and wellness technologies.
What's next for EnsoData?
With this latest infusion of capital, EnsoData is well-positioned to accelerate its product development roadmap and broaden its market reach. The strategic focus will likely center on enhancing the scalability of its AI-native diagnostic platforms and deepening its integration with existing electronic health record systems. As the healthcare industry continues to prioritize data-driven interventions, EnsoData's ability to translate raw physiological signals into meaningful clinical decisions will be a key driver of its long-term growth. Investors are clearly betting on the company's potential to redefine the standard of care in sleep medicine and beyond, leveraging the expertise of its high-profile backers to navigate the complexities of the healthcare innovation ecosystem.
See full EnsoData company page
